Friedreich Ataxia Pipeline Review, H1 Market Size and Share Up to 2016 : Radiant Insights, Inc

Friedreich Ataxia Market Share, Symptoms, Treatment,

Pipeline Review, H1 2016 By Radiant Insights

Friedreich Ataxia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Friedreich Ataxia - Pipeline Review, H1 2016', provides an overview of the

Friedreich Ataxia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Friedreich

Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route

of administration (RoA) and molecule type. The report also covers the descriptive pharmacological

action of the therapeutics, its complete research and development history and latest news and press

releases. Additionally, the report provides an overview of key players involved in therapeutic

development for Friedreich Ataxia and features dormant and discontinued projects.

Read Complete Report With TOC @ http://www.radiantinsights.com/research/friedreich-ataxiapipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy

areas and nearly 3,000 indications. The report is built using data and information sourced from Global

Markets Direct's proprietary databases, company/university websites, clinical trial registries,

conferences, SEC filings, investor presentations and featured press releases from company/university

sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic

review following a stringent set of processes to ensure that all the profiles are updated with the latest

set of information. Additionally, various dynamic tracking processes ensure that the most recent

developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios,

enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Note*: Certain...